Glen Eagle Advisors’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18.1K Hold
288
﹤0.01% 583
2025
Q4
$19.1K Buy
288
+28
+11% +$1.81K ﹤0.01% 592
2025
Q3
$17.5K Hold
260
﹤0.01% 600
2025
Q2
$22.7K Hold
260
﹤0.01% 534
2025
Q1
$17.8K Hold
260
﹤0.01% 559
2024
Q4
$20.2K Sell
260
-114
-30% -$8.44K ﹤0.01% 548
2024
Q3
$25.1K Hold
374
﹤0.01% 531
2024
Q2
$42.4K Buy
374
+114
+44% +$14.4K 0.01% 430
2024
Q1
$36.1K Hold
260
0.01% 458
2023
Q4
$32.3K Hold
260
0.01% 456
2023
Q3
$24.3K Hold
260
0.01% 493
2023
Q2
$33.4K Hold
260
0.01% 437
2023
Q1
$30.2K Hold
260
0.01% 442
2022
Q4
$29.4K Hold
260
0.01% 433
2022
Q3
$20.9K Hold
260
0.01% 478
2022
Q2
$19.4K Hold
260
0.01% 505
2022
Q1
$33.3K Hold
260
0.01% 436
2021
Q4
$34.9K Hold
260
0.01% 428
2021
Q3
$35.5K Sell
260
-200
-43% -$25.2K 0.01% 436
2021
Q2
$49.1K Hold
460
0.02% 375
2021
Q1
$41.3K Sell
460
-120
-21% -$11.3K 0.01% 381
2020
Q4
$53.6K Buy
580
+120
+26% +$10.7K 0.02% 317
2020
Q3
$47.4K Hold
460
0.02% 313
2020
Q2
$46.6K Buy
+460
New +$41.1K 0.02% 296

Other funds holding DXCM

Glen Eagle Advisors's DXCM Position: Q1 2026 in Review

Glen Eagle Advisors held its DexCom (DXCM) position steady in Q1 2026 at 288 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #583.

Glen Eagle Advisors first reported a position in DXCM in Q2 2020 and has held it in 24 quarters since. The position peaked at $53.6K in Q4 2020. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Glen Eagle Advisors held 288 shares of DexCom worth $18.1K as of Q1 2026.
  • Glen Eagle Advisors left its DexCom share count unchanged in Q1 2026.
  • DexCom made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #583 holding.
  • Glen Eagle Advisors first reported a position in DexCom in Q2 2020 and has held it in 24 quarters since.
  • Glen Eagle Advisors's DexCom position peaked at $53.6K in Q4 2020.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.